Linox Smart S DX PME/Master Study
Launched by BIOTRONIK SE & CO. KG · Mar 18, 2010
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with standard ICD indication
- • Be available for follow-up visits on a regular basis at an approved investigational center
- Exclusion Criteria:
- • Patients with standard ICD contra-indication
- • Patients with permanent atrial fibrillation
- • Have a life expectancy of less than six months
- • Are expecting to receive cardiac surgery within 6 months after enrollment
- • Age \< 18 years
- • Not enrolled in another cardiac clinical investigation
About Biotronik Se & Co. Kg
Biotronik SE & Co. KG is a global leader in the development of innovative medical technology, specializing in cardiovascular and endovascular solutions. With a strong commitment to enhancing patient outcomes, the company focuses on advanced therapies and devices, including implantable cardioverter-defibrillators, cardiac resynchronization therapy, and vascular interventions. Biotronik's rigorous research and development initiatives, coupled with its dedication to clinical excellence, position the company at the forefront of medical advancement, striving to improve quality of life for patients worldwide. Through strategic partnerships and a robust clinical trial portfolio, Biotronik continues to drive innovation and set new standards in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials